{"id":"W4409256027","doi":"10.1182/blood.2024026216","title":"Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Stanford Cancer Institute; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Doris Duke Charitable Foundation; Amgen; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Internal medicine; Multiple myeloma; Clinical trial; Refractory (planetary science); Cohort; Surgery; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000685923,0.0002116976,0.0004735132,0.0003053577,0.0001475375,0.0002936907,0.0002691518,0.0001870098,0.0009477243],"category_scores_gemma":[0.0004972094,0.00005818097,0.0003215306,0.0002953133,0.0001388,0.0001626712,0.0001560289,0.0003814762,0.0002134339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00045333,"about_ca_system_score_gemma":0.0003776122,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003348834,"about_ca_topic_score_gemma":0.0008320466,"domain_scores_codex":[0.9997591,0.00008660604,0.00002575131,0.00003287781,0.00006256063,0.00003307496],"domain_scores_gemma":[0.9997172,0.00005735693,0.0001064229,0.00002268695,0.00002818025,0.00006820111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.04754899,0.004505541,0.1651197,0.001019993,0.0009162934,0.00148928,0.0001327796,0.002120358,0.03631905,0.0003126523,0.007277485,0.7332379],"study_design_scores_gemma":[0.02571396,0.1575554,0.7224838,0.0003969808,0.001095589,0.01279472,0.0002159869,0.01073148,0.04117307,0.0006463736,0.02713337,0.00005926038],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894401,0.008224404,0.0004940322,0.0001455319,0.00002997381,0.00008361827,0.0002494564,0.00006603473,0.001266899],"genre_scores_gemma":[0.9980623,0.0009130511,0.0003368118,0.0001116251,0.00002670258,0.00002422039,0.0003121452,0.000003623454,0.0002096733],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009477243,"threshold_uncertainty_score":0.003627598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02212432035080703,"score_gpt":0.3219916211097771,"score_spread":0.2998673007589701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}